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In this issue, Palmer et al. [1] demonstrate that screen-
ing for nephropathy in hypertensive type 2 diabetic patients
and subsequent treatment with renoprotective antihyperten-
sive agents may result in excellent value for money from
the US health care perspective. Estimated costs and ef-
fects were combined in a cost-utility analysis, to express
the incremental costs per quality-adjusted life year (QALY)
for add-on treatment of the angiotensin receptor blocker
(ARB) irbesartan after detection of nephropathy through
screening, compared with conventional antihypertensive
treatment only, in the absence of screening. Nephropa-
thy was defined as microalbuminuria or nephropathy;
i.e. urine albumin excretion (UAE) >20 µg/min (corre-
sponding to a UAE expressed per 24 h > 30 mg/24 h,
with >300 mg/24 h generally defining nephropathy). Such
screening and subsequent ARB treatment—add on to con-
ventional antihypertensive therapy—was estimated to re-
sult in favourable clinical outcomes with only marginally
increasing overall costs. Furthermore, estimated incremen-
tal cost-effectiveness was well below a willingness to pay
(WTP) threshold of US$50 000 per QALY for the USA [2].
Despite the fact that such an absolute quantitative thresh-
old for costs per QALY has to be interpreted with cau-
tion by decision-makers in health care systems, the exact
cost-per-QALY ratio found by the authors at US$20 011
per QALY gained and an estimated 77% probability of
being below this US$50 000 threshold certainly suggest a
favourable pharmacoeconomic profile [1,3]. Palmer et al.
used a Markov model to simulate the progression from
a healthy state to end-stage renal diseases (ESRDs) and
second-order Monte Carlo simulation—both ‘state-of-the-
art’ mathematical techniques in pharmacoeconomics—to
account for multiple parameter uncertainty and to derive
results as listed above [3,4]. In this editorial, we discuss the
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study by Palmer et al. from the viewpoint of pharmacoeco-
nomic science.
How to conduct a pharmacoeconomic analysis?
Pharmacoeconomics is defined as the science focusing on
scarcity of budgets for pharmacotherapeutic interventions;
i.e. that part of health economics with the focus on pharma-
cotherapy. Cost-effectiveness and cost-utility analysis are
the main instruments used in pharmacoeconomics. Cost-
effectiveness analyses relate differences between monetary
costs and benefits (net costs) of an intervention to a clinical
outcome, such as blood-pressure lowering, serious events
avoided or life-years gained. In cost-utility analyses, net
costs of an intervention are related to gains in quality of life
and life years gained (including the quality of those years),
both expressed and aggregated in QALYs [3]. As such,
a QALY integrates gains in survival and gains in quality
during life. For the reimbursement of new drugs—such as
ARBs in the last decade—currently in many countries phar-
macoeconomic research is required and the outcome of it
should indicate that a new drug is ‘cost-effective’ (i.e. be-
low a certain predefined, or thought, threshold for net costs
per outcome considered, usually life-year gained or QALY
gained). Examples in nephrology in recent years exist next
to ARBs: for example, are sorafenib and sunitinib cost-
effective enough in the treatment of renal cell carcinoma to
justify their reimbursement?
Also, such pharmacoeconomic analyses should adhere
to guidelines for the conduct of such studies, guarantee-
ing a minimum quality level. These guidelines are globally
rather uniform and some of them warrant some remarks
here. Firstly, full economic evaluations should ideally be
performed from the societal perspective. The societal per-
spective typically includes indirect non-medical costs of
production losses, next to direct medical costs [5]. Sec-
ondly, these analyses should include all short- and long-
term costs and effects. Ideally, a lifelong perspective is
applied. Therefore, long-term analyses are now required to
support drug reimbursement decisions or implementation
of large-scale interventions, such as screening or vacci-
nation programs. Despite sophisticated methods developed
and used for economic analyses on short-term clinical stud-
ies, such analyses are often considered to be insufficient,
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given the lack of a long-term perspective. Thirdly, long-
term perspectives—beyond clinical-trial horizons—require
the use of adequate modelling techniques, such as Markov
models. Markov models generally enable the analysis of
transitions from one health state (for example, microalbu-
minuria) to another (for example, nephropathy), within a
framework of a predefined number of such health states.
In the model, quality of life is generally defined per state;
durations of stay in these states can easily be analysed over
long time frames.
Palmer et al. [1] developed a Markov model to simulate
disease progression over a 25-year time frame approximat-
ing a lifetime perspective, even more so, as a discount rate
at 3% for money and health gains was applied, following
US-guidelines. In pharmacoeconomic analysis, costs, sav-
ings and health gains are discounted to account for time
preference; i.e. one prefers to receive an amount of money
now rather than receiving that same amount of money in the
future, or one prefers to pay costs in the future over paying
the same amount now (a similar reasoning is assumed for
health). So, pharmacoeconomists attach different values or
utilities to amounts of money or life years that occur on
different moments/periods in time: the higher the discount
rate, the lower the value that is attached to costs, benefits
and health gains that occur in the (distant) future. Recent
discussions have focused on the appropriateness of using
similar discount rates for money and health, for example
with regard to discounting life years [6]. Following that dis-
cussion, the Netherlands recently changed its pharmacoeco-
nomic guideline on discounting to differential discounting:
4% for money and 1.5% for health. Generally, differential
discounting—i.e. relatively low discounting of health com-
pared with money—favours preventive interventions with
health gains in the (distant) future, inclusive screening pro-
grams such as those on albuminuria.
Cost-effectiveness of RAAS-intervening agents in
type 2 diabetic patients
We recently reviewed within-trial analytical and Markov-
model based economic evaluations of Renine Angiotensine
Aldesterone System (RAAS)-intervening agents in type 2
diabetic patients [7], including those studies used by Palmer
et al. [1]: RENAAL, IDNT, IRMA-2 and BENEDICT [8–
11]. Economic outcomes from these studies generally sug-
gest that treatment with RAAS-intervening agents in type 2
diabetic patients, with overt or incipient nephropathy, con-
fers health gains and net cost-savings compared with con-
ventional (non-RAAS) treatment [7,12]. In particular, delay
of renal disease may confer relevant cost-savings in terms
of ESRD, dialyses and kidney transplantations averted. Ad-
ditionally, it has been shown that benefits can be expected
in reducing cardiovascular events [7].
Favourable pharmacoeconomic outcomes for treatment
may justify screening, to identify those who may benefit
from such treatment. Thus, Palmer et al. [1] argue that
screening for albuminuria in the specific population of hy-
pertensive type 2 diabetic patients and subsequent start of
renoprotective ARB treatment in those found positive will
result in excellent value for money. It is still difficult to
definitely assess the relative therapeutic values of ARBs
in relation to ACE inhibitors. Indications exist to show that
ACE-inhibitor treatment results in similar beneficial effects
on renal disease progression and occurrence of cardiovas-
cular events as ARBs, both in type 2 diabetic patients as
well as in non-diabetic patients [11,13,14]. Except for the
DETAIL-trial, however, there are no nephrological studies
comparing the effectiveness of ACE inhibitors and ARBs
on a head-to-head basis for specific nephrological end-
points [14]. Indirect comparison of both classes of drugs
is also difficult. Most trials with ACE inhibitors are par-
tially placebo-controlled, often with, as a result, better blood
pressure control in the ACE inhibitor groups, whereas most
ARB trials showed comparable blood pressure control in
the experimental and control groups [7,13]. Indirect com-
parisons are therefore likely to favour ACE-inhibitors over
ARBs.
One study simulated cost-effectiveness of universal
ACE-inhibitor treatment for type 2 diabetic patients—
irrespective of both blood pressure and albuminuria
levels—and found this to be highly cost-effective [15]. So,
beyond discussions on screening for albuminuria in type 2
diabetic patients, universal treatment of such patients with
RAAS-intervening agents is already under consideration.
On the one hand, this will save screening costs, and on the
other hand drug costs will increase, which is particularly
relevant if drugs are used prior to patent expiry. Obviously,
the topic warrants further pharmacoeconomic analysis, in-
cluding exploring the impact of price reductions as the first
ACE inhibitors are now becoming off-patent, enhancing the
economic profile of these agents.
Cost-effectiveness of screening in the general
population
Economic evaluation based on the outcomes of the IDNT
study in combination with the IRMA-2 study previously
showed that ARB-treatment results in higher cost-savings
if applied in the early stage of microalbuminuria compared
with late overt diabetic nephropathy, both in US and Euro-
pean settings [16]. This suggests that the earlier the treat-
ment is started, the better it is for hypertensive type 2 di-
abetic patients. Would this also apply for the non-diabetic
population with albuminuria? Should we screen for mi-
croalbuminuria (UAE > 30 mg/24 h) and/or nephropathy
(UAE > 300 mg/24 h) in this population as well, and would
this be cost-effective? The PREVEND (Prevention of RE-
nal and Vascular ENd stage Disease) study, as well as other
studies, showed that microalbuminuria (UAE>30 mg/24 h)
presents an independent risk-factor for renal disease and
cardiovascular events, also in the non-diabetic population
[17]. As long as all effects in terms of renal and cardiovas-
cular outcomes and proper cost estimates are considered,
there are certainly indications that albuminuria-based ‘test-
and-treat’ strategies could be a successful tool, resulting
in a reduced number of renal and cardiovascular outcomes
and possibly a favourable cost-effectiveness [18–20].
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Boulware et al. [18] estimated that annual screening for
dipstick protenuria by general practitioners may be cost-
effective to prevent ESRD in the US setting, except if lim-
ited to only elderly or hypertensive persons. However, large
groups of normotensive and non-elderly groups remain,
with net costs per QALY estimates that are generally con-
sidered not cost-effective. Previously, however, we argued
that several rather study-specific factors determine these
negative results [19]. In particular, (i) the general practi-
tioner setting may be unnecessarily expensive and much
cheaper screening might be achieved if subjects are re-
quested to send a first morning void urine sample by post
to a central laboratory, as done in the PREVEND study,
or using other potentially efficient ways such as dipstick
self-tests; (ii) the yield of the screening might be relevantly
increased if instead of only proteinuric, microalbuminuric
persons are also treated and (iii) inclusion of beneficial ef-
fects of RAAS treatment on cardiovascular events—next to
ESRD—will relevantly enhance cost-effectiveness.
As a part of the observational PREVEND-study, a ran-
domized clinical trial was undertaken (PREVEND-IT: Pre-
vention of REnal and Vascular ENstage Disease Inter-
vention Trial), in which fosinopril treatment was shown
to result in a statistically significant reduction in albu-
minuria and a strong trend towards significant differ-
ence in cardiovascular outcomes in a non-diabetic, albu-
minuric and primarily normotensive population [20]. The
PREVEND-IT economic evaluation indicated a favourable
cost-effectiveness of screening for high–normal albumin-
uria (UAE > 15 mg/24 h) and subsequent treatment with the
ACE inhibitor fosinopril to prevent cardiovascular events
[20]. This indicates that—next to screening in specific
patient populations, such as hypertensive type 2 diabetic
patients—screening of the general population for albu-
minuria could be a cost-effective strategy. Such a strat-
egy is beneficial to prevent cardiovascular events in (mi-
cro)albuminuric persons, whereas it may be expected to pre-
vent ESRD especially in macroalbuminuric persons. Thus,
nephrological profit in albuminuria levels and ESRD is
obtained in the slipstream of cardiovascular disease pre-
vention.
Conclusion
In conclusion, favourable economic profiles in treatment
of type 2 diabetic patients with nephropathy were found
for ARBs. This favourable profile justifies screening for
nephropathy and subsequent ARB treatment. As early treat-
ment (starting in the stage of microalbuminuria) was found
to be economically superior to late treatment (starting in
the stage of overt nephropathy), a strong case exists for
screening for albuminuria in diabetic type 2 patients and
subsequent treatment. Possibly, this effect might be extrap-
olated to ACE inhibitors. In fact, for ACE inhibitors, uni-
versal treatment of all type 2 diabetic patients has even
been suggested as cost-effective. For a decision on whether
to prefer ARBs or ACE inhibitors, head-to-head trials are
needed or at least sound indirect comparisons—comparing
the effectiveness of both types of agents with non-RAAS-
intervening agents at similar blood pressure control.
Further research is needed to explore the benefits of
screening for albuminuria in the non-diabetic general pop-
ulation, and the corresponding economic profile of such
a screening. For example, results on favourable cost-
effectiveness from the Dutch PREVEND study require con-
firmation in other settings. Next to renal disease, it is im-
portant to include benefits of screening and treatment on
cardiovascular events in such cost-effectiveness analyses.
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